Published • loading... • Updated
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
Summary by WBOC 16
4 Articles
4 Articles
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for ...
BEIJING, May 07, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for…
Coverage Details
Total News Sources4
Leaning Left1Leaning Right1Center2Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
